Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
Cancer
DRUG: Nexavar (Sorafenib, BAY43-9006)
To determine the pharmacokinetics and safety of cyclophosphamide when co-administered with 400 mg BID sorafenib and doxorubicin administered, 6 weeks
To evaluate the tumor response to the combination of cyclophosphamide, doxorubicin and sorafenib, 6 weeks
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients